Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker VTRS · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 14, 2026 | DIPENTUM OLSALAZINE SODIUM | VTRS Mylan Spclt Viatris | New drug (NDA), supplement Labeling | NDA019715 ↗ |
| Oct 14, 2026 | MESALAMINE, ROWASA MESALAMINE | VTRS Mylan Speciality LP | New drug (NDA), supplement Labeling | NDA019618 ↗ |
| Oct 14, 2026 | VALACYCLOVIR HYDROCHLORIDE VALACYCLOVIR HYDROCHLORIDE | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA078518 ↗ |
| Oct 8, 2026 | CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA075091 ↗ |
| Oct 7, 2026 | AMNESTEEM ISOTRETINOIN | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement REMS | ANDA075945 ↗ |
| Oct 2, 2026 | CLOZAPINE CLOZAPINE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA075417 ↗ |
| Oct 2, 2026 | CLOZAPINE CLOZAPINE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA075417 ↗ |
| Oct 2, 2026 | CLOZAPINE CLOZAPINE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA075417 ↗ |
| Sep 30, 2026 | INDOMETHACIN INDOMETHACIN | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA202139 ↗ |
| Sep 23, 2026 | SPIRONOLACTONE SPIRONOLACTONE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA040424 ↗ |
| Sep 15, 2026 | AMNESTEEM ISOTRETINOIN | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA075945 ↗ |
| Sep 1, 2026 | NEVIRAPINE NEVIRAPINE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA205651 ↗ |
| Aug 21, 2026 | AMNESTEEM ISOTRETINOIN | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA075945 ↗ |
| Aug 14, 2026 | BUPRENORPHINE AND NALOXONE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | VTRS Mylan Technologies | Generic (ANDA), supplement REMS | ANDA211785 ↗ |
| Aug 14, 2026 | BUPRENORPHINE AND NALOXONE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | VTRS Mylan Technologies | Generic (ANDA), supplement REMS | ANDA207607 ↗ |
| Aug 11, 2026 | SAXAGLIPTIN AND METFORMIN METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA205981 ↗ |
| Aug 11, 2026 | METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA200690 ↗ |
| Aug 11, 2026 | METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA075973 ↗ |
| Aug 10, 2026 | SCOPOLAMINE SCOPOLAMINE | VTRS Mylan Technologies | Generic (ANDA), supplement Labeling | ANDA203753 ↗ |
| Aug 10, 2026 | SCOPOLAMINE SCOPOLAMINE | VTRS Mylan Technologies | Generic (ANDA), supplement Labeling | ANDA203753 ↗ |
| Aug 7, 2026 | FOSAPREPITANT FOSAPREPITANT DIMEGLUMINE | VTRS Mylan Labs Ltd | Generic (ANDA), supplement Labeling | ANDA204015 ↗ |
| Aug 5, 2026 | FENOFIBRATE FENOFIBRATE | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA204475 ↗ |
| Aug 4, 2026 | SAXAGLIPTIN AND METFORMIN METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA205981 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE MOFETIL MYCOPHENOLATE MOFETIL HYDROCHLORIDE | VTRS Mylan Labs Ltd | Generic (ANDA), supplement REMS | ANDA203859 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE MOFETIL MYCOPHENOLATE MOFETIL | VTRS Mylan | Generic (ANDA), supplement REMS | ANDA065521 ↗ |
| Jul 29, 2026 | MYCOPHENOLATE MOFETIL MYCOPHENOLATE MOFETIL | VTRS Mylan | Generic (ANDA), supplement REMS | ANDA065520 ↗ |
| Jul 28, 2026 | GWYN LO ETHINYL ESTRADIOL; NORELGESTROMIN | VTRS Viatris Specialty | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA219990 ↗ |
| Jul 28, 2026 | SUGAMMADEX SUGAMMADEX SODIUM | VTRS Mylan | Generic (ANDA) UNKNOWN | ANDA213915 ↗ |
| Jul 22, 2026 | METHYLPHENIDATE METHYLPHENIDATE | VTRS Mylan Tech Viatris | Generic (ANDA), supplement Labeling | ANDA206497 ↗ |
| Jul 22, 2026 | METHYLPHENIDATE METHYLPHENIDATE | VTRS Mylan Tech Viatris | Generic (ANDA), supplement Labeling | ANDA206497 ↗ |
| Jul 16, 2026 | DOXEPIN HYDROCHLORIDE DOXEPIN HYDROCHLORIDE | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA070791 ↗ |
| Jun 26, 2026 | METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA200690 ↗ |
| Jun 26, 2026 | METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLORIDE | VTRS Mylan Pharmaceuticals Inc | Generic (ANDA), supplement Labeling | ANDA200690 ↗ |
| Jun 25, 2026 | FERRIC CARBOXYMALTOSE FERRIC CARBOXYMALTOSE | VTRS Mylan | Generic (ANDA) UNKNOWN | ANDA217769 ↗ |
| Jun 25, 2026 | FERRIC CARBOXYMALTOSE FERRIC CARBOXYMALTOSE | VTRS Mylan | Generic (ANDA) UNKNOWN | ANDA217076 ↗ |
| Jun 25, 2026 | FERRIC CARBOXYMALTOSE FERRIC CARBOXYMALTOSE | VTRS Mylan Labs Ltd | Generic (ANDA) UNKNOWN | ANDA212572 ↗ |
| Jun 25, 2026 | AMLODIPINE AND ATORVASTATIN AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA200465 ↗ |
| Jun 18, 2026 | BUPRENORPHINE BUPRENORPHINE | VTRS Mylan Tech Viatris | Generic (ANDA), supplement REMS | ANDA210162 ↗ |
| Jun 18, 2026 | TRAMADOL HYDROCHLORIDE TRAMADOL HYDROCHLORIDE | VTRS Mylan | Generic (ANDA), supplement REMS | ANDA205257 ↗ |
| Jun 18, 2026 | FENTANYL FENTANYL | VTRS Mylan Technologies | Generic (ANDA), supplement REMS | ANDA076258 ↗ |
| Jun 15, 2026 | LIRAGLUTIDE LIRAGLUTIDE | VTRS Mylan Institutional | Generic (ANDA) UNKNOWN | ANDA213155 ↗ |
| Jun 12, 2026 | DIVALPROEX SODIUM DIVALPROEX SODIUM | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA077567 ↗ |
| Jun 8, 2026 | ESTRADIOL ESTRADIOL | VTRS Mylan Technologies | Generic (ANDA), supplement Labeling | ANDA075182 ↗ |
| Jun 8, 2026 | ESTRADIOL ESTRADIOL | VTRS Mylan Technologies | Generic (ANDA), supplement Labeling | ANDA075182 ↗ |
| Jun 8, 2026 | ESTRADIOL ESTRADIOL | VTRS Mylan Technologies | Generic (ANDA), supplement Labeling | ANDA075182 ↗ |
| May 27, 2026 | METHOTREXATE METHOTREXATE SODIUM | VTRS Mylan | Generic (ANDA), supplement Labeling | ANDA081235 ↗ |
| May 8, 2026 | LEVETIRACETAM IN SODIUM CHLORIDE LEVETIRACETAM | VTRS Mylan Labs Ltd | Generic (ANDA) UNKNOWN | ANDA218364 ↗ |
| May 7, 2026 | ACETAZOLAMIDE ACETAZOLAMIDE SODIUM | VTRS Mylan Asi | Generic (ANDA), supplement Labeling | ANDA200880 ↗ |
| Apr 27, 2026 | LENALIDOMIDE LENALIDOMIDE | VTRS Mylan | Generic (ANDA), supplement REMS | ANDA213912 ↗ |
| Apr 27, 2026 | POMALIDOMIDE POMALIDOMIDE | VTRS Mylan | Generic (ANDA), supplement REMS | ANDA210275 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates